{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edetate+Disodium", "query": { "intervention": "Edetate Disodium" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edetate+Disodium&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T03:05:01.294Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00001849", "title": "New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cushing Syndrome", "Endocrine Disease" ], "interventions": [ { "name": "Pentetreotide", "type": "DRUG" }, { "name": "18F-DOPA", "type": "DRUG" }, { "name": "CT scan", "type": "DEVICE" }, { "name": "MRI", "type": "DEVICE" }, { "name": "18-FDG", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 95, "start_date": "1999-05-20", "completion_date": "2019-04-26", "has_results": true, "last_update_posted_date": "2021-04-14", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001849" }, { "nct_id": "NCT04829344", "title": "A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anesthesia, Local" ], "interventions": [ { "name": "AG-920", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Genomics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2021-03-30", "completion_date": "2021-05-10", "has_results": true, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "McAllen, Texas", "locations": [ { "city": "McAllen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04829344" }, { "nct_id": "NCT00001575", "title": "Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin's Disease", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Y-90 Humanized Anti-Tac", "type": "BIOLOGICAL" }, { "name": "Calcium-DTPA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 87, "start_date": "1997-04", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001575" }, { "nct_id": "NCT00375830", "title": "Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Bone scan", "type": "PROCEDURE" }, { "name": "99mTc-methyl diphosphonate", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET) scan", "type": "PROCEDURE" }, { "name": "18F-Fludeoxyglucose (18F-FDG)", "type": "DRUG" }, { "name": "Computed Tomography (CT) scan", "type": "PROCEDURE" }, { "name": "18F-Sodium Fluoride (18F-NaF)", "type": "DRUG" }, { "name": "Whole Body Magnetic Resonance Imaging (WB-MRI) scan", "type": "PROCEDURE" }, { "name": "Gadopentetate dimeglumine", "type": "DRUG" }, { "name": "Gadofosveset", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2006-01", "completion_date": "2019-03-14", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00375830" }, { "nct_id": "NCT04078191", "title": "Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tc 99m tilmanocept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Navidea Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2021-09-14", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 2, "location_summary": "Beverly Hills, California • Chicago, Illinois", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04078191" }, { "nct_id": "NCT00043017", "title": "Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "MRI/MRS", "type": "PROCEDURE" }, { "name": "gadopentetate dimeglumine", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "American College of Radiology Imaging Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 356, "start_date": "2002-05", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2013-10-09", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043017" }, { "nct_id": "NCT00874887", "title": "A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anti-biotic Resistance" ], "interventions": [ { "name": "moxifloxacin 0.5% HCI ophthalmic solution", "type": "DRUG" }, { "name": "gatifloxacin ophthalmic solution 0.3%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 66, "start_date": "2009-03", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-12-19", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874887" }, { "nct_id": "NCT02733185", "title": "Trial to Assess Chelation Therapy 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Myocardial Infarction" ], "interventions": [ { "name": "disodium EDTA", "type": "DRUG" }, { "name": "Oral Multi Vitamins/Minerals (OMVM)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo disodium EDTA", "type": "DRUG" }, { "name": "Placebo Oral Multi Vitamins/Minerals (OMVM)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Mt. Sinai Medical Center, Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1000, "start_date": "2016-10-01", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "Miami Beach, Florida", "locations": [ { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02733185" }, { "nct_id": "NCT02112097", "title": "ASIS for Enbrel in Plaque Psoriasis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plaque Psoriasis." ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 12", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 24", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 36", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 24", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 36", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 12", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 24", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 36", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 12", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 24", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 36", "type": "DRUG" }, { "name": "Adverse Reactions of Enbrel subcutaneously", "type": "DRUG" }, { "name": "Adverse Reactions of Enbrel subdermally at Week 36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ASIS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02112097" }, { "nct_id": "NCT02683421", "title": "Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tilmanocept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Navidea Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 18, "start_date": "2016-07", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-09-13T03:05:01.294Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02683421" } ] }